US Human Microbiome Therapeutics Industry Outlook 2024-2031: Robust Clinical Trials and Biotech Innovations Fuel Market Expansion

The Global Human Microbiome Therapeutics Market was valued at US$ 960 million in 2024 and is projected to reach US$ 6.7 billion by 2034, registering a CAGR of 21.5% during the forecast period. Growth is driven by the rising incidence of gastrointestinal and metabolic diseases, significant clinical validation of live biotherapeutic products (LBPs), and growing regulatory support for microbiome-based therapies.

Positioned at the forefront of next-generation medicine, the field is experiencing a surge in industry-academia collaborations, strategic investments, and late-stage clinical trials targeting conditions such as recurrent Clostridioides difficile infection, inflammatory bowel disease and metabolic syndrome. This momentum is accelerating the commercialization of standardized microbiome treatments and transforming these therapies from experimental concepts into mainstream clinical assets.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/human-microbiome-therapeutics?sai-v

The Human Microbiome Therapeutics Market involves treatments that target and modulate the body's microbial communities to restore balance, enhance immunity, and manage diseases linked to gut and metabolic health.

Key Developments

✅ June 2025 (United States):Seres Therapeutics announced the expansion of its manufacturing capacity for microbiome-based therapeutics to meet rising demand following the success of its VOWSTTM launch for recurrent C. difficile infection. The company aims to scale production for pipeline candidates targeting inflammatory and metabolic disorders.

✅ April 2025 (United States):Finch Therapeutics entered into a research collaboration with a major U.S. academic center to explore engineered microbiome formulations for ulcerative colitis and Crohn's disease. The partnership strengthens Finch's focus on next-generation microbial therapeutics using precision bacterial consortia.

✅ May 2025 (Japan):Eisai Co., Ltd. collaborated with a biotechnology startup to study gut-brain axis modulation for neurodegenerative diseases. The partnership integrates microbiome-based therapy with digital biomarkers to enhance clinical monitoring and treatment personalization.

✅ February 2025 (Japan):The University of Tokyo, in partnership with a domestic biotech firm, launched clinical research on microbiome-based interventions for metabolic syndrome. The study aims to identify specific bacterial strains linked to glucose regulation and weight management.

Mergers & Acquisitions

✅ March 2025 (United States):A U.S.-based biopharma company acquired a microbiome-focused startup specializing in live biotherapeutic drug design, enhancing its capabilities in microbiota-targeted therapies for gastrointestinal and immune-related disorders.

✅ January 2025 (Japan):A leading Japanese pharmaceutical company completed the acquisition of a microbiome analytics firm to strengthen its R&D capabilities in personalized probiotic drug development.

Market Outlook
"Microbiome therapeutics are shaping the next frontier in precision medicine."

◆ United States: Market growth is driven by FDA-approved live biotherapeutic products and expanding clinical trials addressing infectious, metabolic, and neurological diseases.

◆ Japan: Accelerating R&D collaborations between pharma and biotech firms are focusing on gut-brain and gut-metabolic research, backed by supportive government funding.

◆ Globally, the human microbiome therapeutics market is expected to expand rapidly through 2030, propelled by advancements in synthetic biology, personalized medicine, and regulatory clarity for live biotherapeutic

Key Players:

BaseClear BV | Clinical Microbiomics AS | Locus Biosciences | Microbiome Insights Inc. | Microbiome Therapeutics LLC | MR DNA | Second Genome | uBiome | Molzym GmbH | Zymo Research Corp

Key Highlights:

• BaseClear BV generated around USD 40 million, focusing on microbiome sequencing and genomic analysis services.
• Clinical Microbiomics AS reported steady growth with human microbiome data analytics for personalized medicine.
• Locus Biosciences secured USD 30 million in funding to advance CRISPR-enhanced bacteriophage therapies.
• Microbiome Insights Inc. achieved strong expansion through clinical and environmental microbiome profiling.
• Microbiome Therapeutics LLC develops microbiome-based drugs, contributing to the gut health therapeutics market.
• MR DNA reported growth in next-gen sequencing and microbial profiling solutions across research labs.
• Second Genome collaborates with pharma giants, focusing on microbiome-based biomarkers and drug discovery.
• uBiome previously pioneered consumer microbiome testing, influencing data-driven health insights.
• Molzym GmbH provides molecular diagnostics and microbial DNA removal kits for clinical applications.
• Zymo Research Corp generated about USD 120 million, recognized for DNA/RNA purification and microbiome analysis kits.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=human-microbiome-therapeutics?sai-v
(Purchase 2 or more Repots and get 50% Discount)

Market Drivers & Growth:

The growing prevalence of chronic diseases such as inflammatory bowel disease, obesity, and diabetes is boosting demand for "microbiome-based therapies" that restore gut microbial balance.

Advancements in "personalized medicine" are enabling targeted microbiome interventions based on individual microbial profiles, enhancing therapeutic outcomes.

Increased investments from biotech and pharmaceutical firms in live biotherapeutic products (LBPs), engineered microbial consortia, and fecal microbiota transplantation (FMT) are driving innovation in the market.

Supportive "regulatory frameworks" and growing real-world evidence are accelerating the clinical development and approval process for microbiome therapeutics.

The global market is witnessing significant momentum, fueled by clinical breakthroughs, funding inflows, and expanding therapeutic applications beyond gastrointestinal disorders.

FDA Approvals & Market Access:

The U.S. FDA approved Rebyota (Ferring Pharmaceuticals) and Vowst (Seres Therapeutics) as the first oral "microbiome-based live biotherapeutic products" for the prevention of recurrent Clostridioides difficile infection (CDI), marking a major milestone in microbiome therapy commercialization.

These approvals have opened the door for faster "market access pathways" and enhanced confidence among developers, investors, and healthcare providers.

Regulatory authorities in Japan and the EU are developing harmonized guidelines for microbiome-based drug approval, supporting international clinical collaboration and cross-border market expansion.

Regional Insights:

United States: Dominates the market due to early FDA approvals, robust research funding, and the presence of leading biotech innovators specializing in microbiome therapeutics.

Japan: Gaining momentum with national initiatives promoting "microbiome medicine," focusing on gut-brain health, metabolic syndromes, and oncology-related applications.

Europe: A strong player in research and GMP-grade microbiome manufacturing, with increasing investments from France, Germany, and the U.K. to support clinical trials.

Asia-Pacific: Emerging as a key growth hub led by China and India, with growing healthcare infrastructure and government support for precision microbiome-based therapies.

Key Segments:

➥ By Technology:
Includes Shotgun, Targeted Gene, RNA, and Whole Genome Sequencing, offering precise mapping of genetic information for disease detection and treatment development.

➥ By Technique:
Key techniques such as Synthesis by Ligation, Pyrosequencing, and Sanger Sequencing are widely used for identifying mutations, analyzing gene expression, and validating genetic variants.

➥ By Application:
Gene sequencing is driving advancements in Therapeutics, Genetic Screening, Drug Discovery, Biomarker Discovery, and Personalized Medicine, enabling tailored healthcare solutions.

➥ By End User:
Major adopters include Research Institutes, Pharmaceutical, and Biotechnology Companies, leveraging sequencing technologies for innovation in genomics-based drug development and clinical research.

Research Process:

Both primary and secondary data sources have been used in the Global Human Microbiome Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/human-microbiome-therapeutics?sai-v

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.